We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Jaguar Health Inc (JAGX) USD0.0001

Sell:$1.02 Buy:$1.03 Change: $0.05325 (5.45%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.02
Buy:$1.03
Change: $0.05325 (5.45%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.02
Buy:$1.03
Change: $0.05325 (5.45%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Contact details

Address:
200 PINE STREET SUITE 400
SAN FRANCISCO
94104
United States
Telephone:
+1 (415) 3718300
Website:
https://jaguar.health/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
JAGX
ISIN:
US47010C8055
Market cap:
$12.15 million
Shares in issue:
11.80 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Lisa Conte
    President, Chief Executive Officer, Director
  • Carol Lizak
    Chief Financial Officer
  • Pravin Chaturvedi
    Chief Scientific Officer
  • Jonathan Wolin
    Chief of Staff, General Counsel, Chief Compliance Officer
  • Ian Wendt
    Chief Commercial Officer
  • Steven King
    Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.